Atara Biotherapeutics, Inc. to Present at the 2015 Jefferies Immuno-Oncology Summit

SOUTH SAN FRANCISCO, Calif., April 13, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that Isaac Ciechanover, M.D., the company's Chief Executive Officer, will present at the 2015 Jefferies Immuno-Oncology Summit on Wednesday, April 15, 2015 at 11:00 am EDT in Boston.

About Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with debilitating diseases. Atara's lead programs target myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. In September 2014, Atara Biotherapeutics entered into an exclusive option agreement with Memorial Sloan Kettering Cancer Center (MSK), under which it has the right to license (pursuant to a negotiated form of license agreement) the exclusive, worldwide rights to three clinical stage T-cell programs, including Epstein-Barr virus-targeted cytotoxic T lymphocytes, which recently received breakthrough therapy designation from the Food and Drug Administration, as well as other T-cell programs that are discovered or developed by MSK pursuant to sponsored research funded by the company.

CONTACT: INVESTOR CONTACT:
         Tina Gullotta, Atara Biotherapeutics, Inc.
         650-741-1613
         tgullotta@atarabio.com

         MEDIA CONTACT:
         Susan Heins, Pure Communications, Inc.
         864-286-9597
         susan@purecommunicationsinc.com
Source: Atara Biotherapeutics